The First Diagnostic: Is the Problem Really Money?
At this point, Spain’s ecosystem has two facts that appear to conflict. Finance is a persistent condition for entrepreneurial activity, and Spain has a real shortage of large domestic rounds for some scaleup-potential firms. Yet the evidence also shows that productive entrepreneurship depends on demand, talent and additional conversion conditions such as knowledge, culture and support. This checkpoint connects those ideas into a practical judgment: before prescribing more capital, locate the transition that is actually failing.
A cheque is a tool, not a milestone
Capital is easy to discuss because it is visible. A funding round has an amount, a date and a named investor. It can be counted and compared. The progress it is meant to purchase is less tidy. A company may use a round to hire engineers, build a product, run experiments, win a first customer, enter another market or prepare for a later financing event. These are different uses of money, with different evidence and different failure modes.
That is why “finance matters” is compatible with “more VC alone cannot fix the system.” If a company has no runway to complete a necessary technical or commercial step, capital may be the binding constraint. If it has runway but cannot find the people to execute, the next cheque does not solve the problem. If the team can build but no customer will test or buy the product, money can prolong development without creating validation. If demand exists but a regulatory or procurement process takes too long, the venture may run out of time while waiting for the market to open.
Spain’s data make this distinction concrete. Ordinary SME credit is not absent: fewer than 7% of Spanish SMEs reported being credit constrained in the 2023 EIB survey. Early-stage VC has expanded, and public instruments such as ENISA participatory loans can give firms time when they are too risky for conventional lending but not yet ready for a conventional VC round. The sharpest gap appears later, with more than 91% of recorded domestic rounds below EUR 5 million and domestic funds financing a minority of the largest recorded deals.
The correct conclusion is conditional. A company with a validated product, capable team and expanding market may genuinely need larger, more specialised and patient capital. A company without those complements may need something else first. The funding gap is real for the first group, but a national policy cannot identify the group simply by counting startups or increasing the total amount invested.
A useful diagnostic asks four questions in order.
- Which transition has stalled? Is the company trying to move from idea to proof, proof to a product, product to a first customer, early revenue to repeatable sales, or domestic activity to international scale?
- What evidence should the next resource produce? A technical demonstration, a qualified team, a paying customer, regulatory approval, repeatable distribution or a credible path to a larger market?
- Which condition is missing or poorly connected? Is the obstacle capital, talent, knowledge transfer, demand, regulation, network access or the quality of specialised support?
- What would change the diagnosis? A new customer contract, successful hiring, a completed pilot, an investment commitment or evidence that a public programme reaches its intended stage should update the judgment.
This sequence prevents two common errors. The first is indiscriminate subsidy: every stalled venture is treated as a funding problem. The second is capital denial: because money is not sufficient, it is treated as unimportant.